Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tyler Michalka has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feline Leukemia Virus and Feline Immunodeficiency Virus in Domestic and Free-Roaming Cats: A Systematic Review and Meta-Analysis of North American Prevalence, Risk Factors, and Diagnostic Considerations, 1987–2024

    by Tyler Michalka, Csaba Varga, Maged Gomaa Hemida

    Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are important retroviral pathogens affecting domestic and free-roaming cats worldwide. This systematic review and meta-analysis synthesized prevalence, risk factors, diagnostic considerations, and epidemiological trends in North America from 1987 to 2024. Following the PRISMA framework, studies from the United States and Canada were evaluated using data from 285,080 cats for FIV and 183,296 cats for FeLV. Pooled prevalence was 4.02% (95% CI: 3.60–4.49%) for FIV and 3.57% (95% CI: 3.13–4.07%) for FeLV, with substantial heterogeneity among studies. Older age, male sex, intact male status, outdoor access, poor health, and feral or shelter status were associated with increased infection prevalence. Prevalence remained relatively stable overall but varied geographically and across population types. Diagnostic limitations, particularly detection of regressive FeLV infection, may influence prevalence estimates. These findings support integrated surveillance, improved diagnostic strategies, vaccination, and targeted population management.

  • Top Cited Papers
    Open Access

    Multi-Epitope DNA-Based Feline Immunodeficiency Virus Vaccine Construct Designed by Immunoinformatic and Machine Learning Tools as a Surrogate Model for HIV Vaccine Development

    by Tyler Michalka, Abid Ullah Shah, Tiffany Liang, Maged Gomaa Hemida

    Feline immunodeficiency virus (FIV) is a lentivirus that exhibits significant structural and pathological similarities to human immunodeficiency virus (HIV), establishing it as a valuable model for HIV vaccine development. In this study, artificial intelligence (AI) and immunoinformatics were employed to design a novel multi-epitope DNA vaccine targeting conserved regions of the FIV gag, pol, and env genes. Predicted B-cell and T-cell epitopes were evaluated for their capacity to induce strong immune responses while minimizing allergenic or toxic effects and were linked to the immune adjuvant PADRE. Structural analysis indicated that the vaccine construct is stable, soluble, and biocompatible, with a well-folded tertiary structure that binds Toll-like receptor 9 (TLR9) and elicits robust humoral and cellular immune responses. These findings identify a promising FIV vaccine candidate and provide insights for the development of next-generation HIV vaccines.


  • Open Access

    Multi-Epitopes DNA Based Feline Immunodeficiency Virus Vaccine Constructs Designed by ImmunoInformatics and Machine Learning Tools as a Surrogate Model for the HIV Vaccine Development

    by Tyler Michalka, Abid Shah, Tiffany Liang, Maged Hemida

    Feline immunodeficiency virus (FIV) is a lentivirus sharing significant structural and pathological similarities to human immunodeficiency virus (HIV), making it a valuable surrogate model for HIV vaccine design and development. Currently, there is no available effective vaccine could protect cats against FIV infection. This study aims to use some artificial intelligence and immunoinformatic to design a novel multi-epitope DNA vaccine targeting some conserved regions of FIV’s gag, pol, and env genes. The mapped B and T-cell epitopes across the key proteins of the FIV genomes were screened for their ability to trigger strong immune responses, while avoiding allergenic or toxic responses and were linked to the immune adjuvant PADRE. Analysis of the vaccine construct revealed a stable, soluble, and biocompatible vaccine construct with a well-folded tertiary structure capable of binding toll-like receptor 9 (TLR9) and eliciting a robust humoral and cellular immune response. These results demonstrate a promising FIV vaccine candidate with potential insight into future directions in next generation HIV vaccines. Further experimental validation is required to confirm the potential protective power of these putative vaccines in the protection of cats against FIV natural field infection.